- Home
- TCBI vs EWTX Comparison
TCBI vs EWTX Comparison
Compare TCBI & EWTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | TCBI | EWTX |
|---|---|---|
| Founded | 1996 | 2017 |
| Country | United States | United States |
| Employees | 1785 | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.5B | 3.7B |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | TCBI | EWTX |
|---|---|---|
| Price | $102.87 | $45.10 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 13 | 6 |
| Target Price | ★ $100.92 | $39.00 |
| AVG Volume (30 Days) | 534.5K | ★ 1.6M |
| Earning Date | 04-23-2026 | 05-07-2026 |
| Dividend Yield | ★ 0.81% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $14.76 | N/A |
| Revenue Next Year | $7.47 | N/A |
| P/E Ratio | $15.46 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $75.41 | $12.31 |
| 52 Week High | $108.92 | $48.40 |
Technical Indicators
Market Signals| Indicator | TCBI | EWTX |
|---|---|---|
| Relative Strength Index (RSI) | 52.76 | 64.16 |
| Support Level | $97.23 | $29.03 |
| Resistance Level | $102.72 | N/A |
| Average True Range (ATR) | 2.38 | 2.71 |
| MACD | -0.09 | 0.66 |
| Stochastic Oscillator | 53.18 | 74.04 |
Price Performance
Historical ComparisonAbout TCBI Texas Capital Bancshares Inc.
Texas Capital Bancshares Inc is a registered bank holding company and a full-service financial services firm that delivers customised solutions to businesses, entrepreneurs and individual customers. It is a secured lender with the majority of the loans held for investment, excluding mortgage finance loans and other national lines of business. Texas Capital has established commercial banking, consumer banking, investment banking and wealth management capabilities.
About EWTX Edgewise Therapeutics Inc.
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is developing novel therapeutics for muscular dystrophies and serious cardiac conditions. The company's product candidates are Sevasemten, EDG-7500, EDG-003, and EDG-15400. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies, including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company's products are currently in different stages of their development, being developed to target key muscle proteins and modulators to address a broad array of muscle diseases.